^PrHUMIRA^® is indicated for the treatment of active moderate to severe HS in adult and adolescent patients (12 to 17 years of age weighing ≥30 kg), who have not responded to conventional therapy (including systemic antibiotics)

Consult the Product Monograph at abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/HUMIRA_PM_EN.pdf for contraindications, serious warnings and precautions, other warnings and precautions, adverse reactions, interactions, dosing, conditions of clinical use and storage and handling. The Product Monograph is also available by calling us at 1-866-848-6472.